All 50 states have enacted some sort of pharmacy benefit manager (PBM) legislation, but a handful are setting the pace in terms of new laws targeting ownership restrictions, transparency requirements, and compensation models.
The White House made news last month with its blueprint to lower drug prices. But it's also important to note that biosimilars will play a crucial role in fostering competition and lowering costs. Biosimilars are the topic of my latest op-ed, "How to Foster Competition While Cutting Drug Costs," published last month in Morning Consult.
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.